PCM
TBIO

Penn Capital Management’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Penn Capital Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,800
Closed -$633K – 168
2023
Q3 		$633K Buy
33,800
+1,604
+5% +$39K 0.06% 129
2023
Q2 		$916K Buy
32,196
+1,958
+6% +$78.2K 0.09% 127
2023
Q1 		$1.69M Sell
30,238
-34,988
-54% -$1.24M 0.17% 119
2022
Q4 		$1.47M Buy
65,226
+11,445
+21% +$311K 0.15% 131
2022
Q3 		$1.61M Buy
53,781
+24,646
+85% +$868K 0.18% 121
2022
Q2 		$944K Buy
+29,135
New +$2.01M 0.1% 144

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Penn Capital Management's TBIO Position: Q4 2023 in Review

Penn Capital Management sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q4 2023, closing a stake of 33,800 shares — an estimated $633K sold.

Penn Capital Management first reported a position in TBIO in Q2 2022 and held it in 6 quarters. The position peaked at $1.69M in Q1 2023. 24 funds tracked by Wall St. Rank hold TBIO as of Q4 2023.

  • Penn Capital Management reported no remaining Telesis Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Penn Capital Management sold 33,800 Telesis Bio, Inc. Common Stock shares in Q4 2023, an estimated $633K.
  • Penn Capital Management first reported a position in Telesis Bio, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
  • Penn Capital Management's Telesis Bio, Inc. Common Stock position peaked at $1.69M in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q4 2023.

Based on Penn Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.